AddGraft Therapeutics is redefining the therapy production and delivery landscape with our one-of-a-kind approach to gene therapy.
Our unique technology promises to circumvent issues associated with toxicity, dose control, eligibility and large transgene size that are keeping current forms of gene therapy from reaching patients today.
We aim to translate our promising pre-clinical
work into the clinic to help people around the world better face a variety of disease with new hope.
Chief Executive Officer
Ryan is a skilled STEM leader with significant experience in management consulting and venture capital. Prior to
co-founding AddGraft, Ryan helped lead healthcare organizations through significant M&A activities.
Here he developed expertise in project management, team leadership and strategic decision making. Ryan is also completing his MBA at the Booth School of Business at the University of Chicago.
Dr. Ming Xu
Chief Science Officer
Dr. Ming Xu is a professor of neurobiology in the Biological Science Division at the University of Chicago.
Over the last 25 years, Dr. Xu’s laboratory has worked to understand the mechanisms of drug addiction and aimed to find possible treatment strategies. With over 100 publications in the field of Neurobiology,
Dr. Xu is world class expert in the study of Neurological Disease and specifically addiction.
Dr. Xiaoyang Wu
Chief Technology Officer
Dr. Xiaoyang Wu is an associate professor of tissue engineering in the Biological Science Division at the University of Chicago. Dr. Wu’s long-term interest is to explore cell signaling and the molecular mechanisms controlling somatic stem cell behavior and somatic gene therapy. His laboratory has significantly advanced our understanding of how skin injuries activate quiescent epidermal stem cells to proliferate and migrate to repair a wound.